Motley Fool Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Motley Fool Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316K	Sell	636 -42,200	-99%	-$18.7M	4.8%	10
2026 Q1	$19.1M	Sell	42,836 -16,701	-28%	-$7.79M	2.16%	8
2025 Q4	$27M	Sell	59,537 -11,812	-17%	-$5.09M	2.09%	10
2025 Q3	$27.9M	Buy	71,349 +17,436	+32%	+$7.29M	1.89%	10
2025 Q2	$24M	Buy	53,913 +20,864	+63%	+$9.61M	1.45%	19
2025 Q1	$16M	Sell	33,049 -3,412	-9%	-$1.59M	0.95%	28
2024 Q4	$14.7M	Sell	36,461 -3,032	-8%	-$1.41M	0.76%	40
2024 Q3	$18.4M	Sell	39,493 -1,747	-4%	-$839K	0.92%	32
2024 Q2	$19.4M	Sell	41,240 -834	-2%	-$362K	0.99%	29
2024 Q1	$17.6M	Buy	+42,074	New	+$17.8M	0.91%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Motley Fool Wealth Management's VRTX Position: Q2 2026 in Review

Motley Fool Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 99% in Q2 2026, selling an estimated $18.7M and leaving 636 shares worth $316K. The position accounts for 4.8% of the portfolio, ranked #10.

Motley Fool Wealth Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $27.9M in Q3 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Motley Fool Wealth Management held 636 shares of Vertex Pharmaceuticals worth $316K as of Q2 2026.
Motley Fool Wealth Management sold 42,200 Vertex Pharmaceuticals shares in Q2 2026, an estimated $18.7M.
Vertex Pharmaceuticals made up 4.8% of Motley Fool Wealth Management's portfolio in Q2 2026, its #10 holding.
Motley Fool Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Motley Fool Wealth Management's Vertex Pharmaceuticals position peaked at $27.9M in Q3 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Motley Fool Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.